News

Almirall: COPD drug approved
Enlarge image

BusinessSpain

Almirall: COPD drug approved

27.07.2012 - Spanish drugmaker Almirall S.A.'s inhaled treatment for lung disease COPD has been approved in all EU member states, plus Iceland and Norway.

The approval by the European Commission was expected after the CHMP gave the twice-daily drug a positive opinion in May covering use as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD). US approval is expected in July.

Florence-based Menarini Group will have joint commercialisation rights across the majority of EU member states (excluding the UK, the Netherlands and the Nordic countries, where Almirall retains sole marketing rights for the product) as well as Russia, Turkey and other CIS countries under the brand name Bretaris Genuair, while Almirall will market the product in Europe as Eklira Genuair.

Almirall's treatment loosens the muscles around the lungs to improve airflow. COPD makes breathing difficult and is often caused by cigarette smoking, which kills between 200,000 and 300,000 people in Europe a year, Almirall said.

http://www.european-biotechnology-news.com/news/news/2012-03/almirall-copd-drug-approved.html

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC0.78 EUR0.00%
  • ACTELION114.40 CHF0.00%
  • ADDEX3.20 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC0.78 EUR0.00%
  • ACTELION114.40 CHF0.00%

TOP

  • WILEX3.43 EUR75.0%
  • BASILEA122.20 CHF16.3%
  • ACTELION114.40 CHF13.5%

FLOP

  • SANTHERA94.55 CHF-10.0%
  • 4SC0.78 EUR-7.1%
  • STRATEC BIOMEDICAL43.49 EUR-6.8%

TOP

  • SANTHERA94.55 CHF2330.6%
  • WILEX3.43 EUR481.4%
  • FORMYCON16.70 EUR106.7%

FLOP

  • CYTOS0.34 CHF-88.7%
  • MOLOGEN5.38 EUR-55.7%
  • BIOFRONTERA1.84 EUR-53.3%

No liability assumed, Date: 28.02.2015